Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Email Alerts

Sign up today and receive company updates straight to your inbox.

Stock Information

Company Overview

IceCure is setting new standards in minimally-invasive tumor therapy for women’s health and interventional oncology. Founded in 2006 to advance the treatment of cancerous tumors, our core technology is based on cryoablation, using liquid nitrogen to create ultra-low freezing temperatures to destroy tumors safely, quickly, and painlessly in a minimally-invasive procedure.

Our ProSense™ cryoablation system, enables rapid minimally-invasive, safe, and effective treatment of breast lesions in-office or ambulatory hospital settings. The system provides physicians with full control over the procedure, ensuring that the treated zone is destroyed while leaving surrounding tissue undamaged. The ProSense™ system is a proven solution for the treatment of benign and malignant breast tumors, as well as renal, lung, and bone cancer. The FDA cleared and CE marked ProSense system is available in the US, Europe, and across Asia in Singapore, Thailand, Japan, and Taiwan.

IR Contacts


IceCure Medical Ltd.
7 Ha’Eshel Street
PO Box 3163
Caesarea 3079504
T: +972-4-623-0333
F: +972-4-623-0222

Investor Relations

IceCure Medical, LTD
Ronen Tsimerman
7 Ha'Eshel St
PO Box 3163
T: +972-4-623-0333

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179

Scroll to the top of the page